Project Grant R01HL174024
Award Date
8/1/25
Completion Date
5/31/29
Dollars Obligated
$741K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Utah, USA
Similar Awards
This Project Grant award of $565,834 from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (CFDA 93.837 Cardiovascular Diseases Research), aims to investigate the long-term impact of early-life respiratory syncytial virus (RSV) infection on the development of childhood asthma. The research will focus on understanding how RSV infection can cause epigenetic modifications in lung epithelial cells that lead to persistent changes in the lung's...
The National Heart, Lung, and Blood Institute (NHLBI), under CFDA 93.837 - Cardiovascular Diseases Research, awarded a $387,116 Project Grant to the University of South Florida. The 5-year grant, effective May 1, 2025, supports research to define the neural mechanisms by which house dust mite (HDM) exposure triggers airway hyperreactivity, a key characteristic of asthma. The research aims to identify the specific sensory nerve subtypes and signaling pathways activated by HDM that lead to...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $207,500 to the University of Southern California to study the role of the MIF/CD74 pathway in group 2 innate lymphoid cells (ILC2) and its impact on airway hyperreactivity and asthma. The key objectives of this 2-year research project are to: 1) Assess the expression patterns of CD74 in the lungs and measure...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $636,843 to The Regents of the University of California, San Francisco (UCSF) to conduct research on targeting the stromal niche for tissue-resident lymphocytes in asthma. The research aims to characterize a targetable stromal factor that alters immune cell accumulation in the lung and define the downstream effects on airway epithelial...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under CFDA Program 93.837 - Cardiovascular Diseases Research, will provide $246,000.00 to the University of Chicago to investigate the immune cell landscape in Amish and Hutterite children and its relationship to asthma risk. The researchers will leverage the natural environmental differences between these two farming populations to generate multi-omic datasets characterizing the transcriptional and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $616,814 to the President and Fellows of Harvard College, Harvard T.H. Chan School of Public Health, to conduct research on the role of microRNAs in regulating airway smooth muscle function and their contribution to asthma. The overarching goal is to establish the in vivo impact of key microRNAs in regulating airway smooth muscle proliferation,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $777,497.00 to The Washington University to study how the circadian clock mediates the adult age, pro-resolution response to viral asthma triggers. The research aims to clarify how the circadian clock operating within alveolar macrophages and airway epithelial cells promotes the resolution of viral inflammation and normal repair...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $347,608 to Biotherapeutics, Inc. to develop a novel, oral, once-daily, immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) characterize the therapeutic efficacy and route of administration of the drug candidate in mouse models of asthma, and 2) determine the translational ability of the therapeutic...
This $177,403 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The funding supports research to disentangle the heterogeneity of asthma, identify distinct asthma endotypes, and investigate biological mechanisms underlying established risk factors. The project will utilize multi-omics data from three cohorts of asthmatic children to analyze the interplay between genetic, epigenetic, and metabolomic...
This Project Grant award for $355,935 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports the development of a novel, oral immunoregulatory therapeutic for the treatment of asthma. The primary objectives are to characterize the therapeutic efficacy and dosing regimen of the compound in mouse models of asthma, and to evaluate its ability to modulate immune function and suppress inflammation in human...